Another instance where a judge blocked the launch of a generic drug pending the outcome of patent litigation: the Galderma* vs Mylan suit with respect to Oracea.
*State University of New York, Galderma’s licensor, is also a plaintiff.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.